RxDoctor Payments Data

Jeet Lund, DO

Pulmonary Disease · New Haven, CTNPI 1275977753

Payments from drug & device makers

$3,108in general payments, 2019–2025

Across 59 payments — averaging $52.68 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Intuitive Surgical$838
  • Pulmonx Corporation$805
  • Pinnacle Biologics, Inc$579
  • Noah Medical Corporation$140
  • Olympus America Inc.$139
  • Mallinckrodt Enterprises LLC$94
  • plus $513 from 12 others

What the payments were for

  • Travel & lodging$1,53149%
  • Food & beverage$1,57751%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,108 in reported general payments places this provider in the 60th percentile of 255 pulmonary disease providers in Connecticut.

See all pulmonary disease providers in Connecticut

Medicare billing

Part B allowed, 2024
$12,143
Medicare patients
44
Services billed
111

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Breztri AerosphereBudesonide/Glycopyr/Formoterol34$26,922
Spiriva RespimatTiotropium Bromide58$21,014
Stiolto RespimatTiotropium Br/Olodaterol Hcl31$11,550
Trelegy ElliptaFluticasone/Umeclidin/Vilanter12$8,749
Wixela InhubFluticasone Propion/Salmeterol47$5,205
BreynaBudesonide/Formoterol Fumarate14$1,946
Albuterol Sulfate HfaAlbuterol Sulfate97$1,643
Pantoprazole Sodium30$275
Prednisone25$179
Azithromycin22$142
Furosemide16$116

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimSpiriva Respimat, Stiolto Respimat$33$32,56389 claims
AstraZenecaBreztri Aerosphere$26$26,92234 claims
GSKTrelegy Ellipta$29$8,74912 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 255 pulmonary disease providers in Connecticut.

Other pulmonary disease in New Haven

See the full list for Connecticut

Where these figures come from

Is this you, or does something look wrong? →